Program
Abiraterone Acetate
Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.
Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.
Drug pageAbiraterone Acetate: every studyMany companies study it; this page follows only the 53 they lead. All 127 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 414 open or running | phase 4since Mar 27, 2015 | May 11, 2007 | none ahead |
| Jiangsu HengRui Medicineits history only | 32 open or running | phase 2since Apr 25, 2021 | Apr 25, 2021 | Dec 2026phase 2 · NCT06568094 |
| Sun Pharmaceutical Industriesits history only | 31 open or running | phase 2since Mar 25, 2016 | Mar 25, 2016 | Dec 31, 2027phase 2 · NCT05422911 |
| Sanofiits history only | 20 open or running | phase 4since Jun 26, 2015 | Jan 4, 2012 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since May 12, 2021 | May 12, 2021 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Aug 11, 2019 | Aug 11, 2019 | none ahead |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Zentiva, k.s.its history only | 10 open or running | phase 1since Mar 2, 2020 | Mar 2, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since May 11, 2007.
- Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more
- Mar 25, 2016Sun Pharmaceutical Industries’ first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02737332 · 53 enrolled · United States
- Oct 31, 2016Phase 2 study in Prostatic NeoplasmsSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
- Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
- Aug 11, 2019Sino Biopharmaceutical’s first study: phase 3 study in Metastatic Castration Resistant Prostate CancerNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04056754 · 268 enrolled · China
- Mar 2, 2020Zentiva, k.s.’s first study: phase 1 study in PharmacokineticsNew to Zentiva, k.s.Zentiva, k.s. · NCT04295161 · 33 enrolled · United Kingdom
- Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
- Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
- Dec 7, 2020Sumitomo Pharma’s first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
- Apr 25, 2021Jiangsu HengRui Medicine’s first study: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)New to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04862091 · 69 enrolled · China
- May 12, 2021Boryung Pharmaceutical’s first study: phase 1 study in Prostatic NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04889651 · 40 enrolled · Korea, Republic of
- Jun 9, 2022Phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911 · 192 planned · United States
- Oct 13, 2023Phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990 · 660 planned
- Aug 21, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094 · 100 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094
- Dec 31, 2027Primary completion: phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911
- Dec 2028Primary completion: phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990
TargetBeta
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06568094Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 100 |
| NCT06099990Neoplasm Metastasis | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 2028 | 660 |
| NCT05422911Neoplasm Metastasis · United States | 2 | Recruiting | Sun Pharmaceutical Industries | Dec 31, 2027 | 192 |
| NCT04889651Prostatic Neoplasms · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jun 8, 2021 | 40 |
| NCT04862091Metastatic Castration-resistant Prostate Cancer (mCRPC) · China | 2 | Completed | Jiangsu HengRui Medicine | Oct 21, 2021 | 69 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04577833Prostatic Neoplasms · United States, Belgium, France and more | 1 | Active, not recruiting | Johnson & Johnson | Oct 15, 2021 | 136 |
| NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 7, 2025 | 696 |
| NCT04295161Pharmacokinetics · United Kingdom | 1 | Completed | Zentiva, k.s. | Nov 8, 2019 | 33 |
| NCT04056754Metastatic Castration Resistant Prostate Cancer · China | 3 | Completed | Sino Biopharmaceutical | Mar 14, 2018 | 268 |
| NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 8, 2021 | 765 |
| NCT02962284Prostatic Neoplasms | 2 | Completed | Sun Pharmaceutical Industries | Mar 2018 | 20 |
| NCT02737332Prostatic Neoplasms · United States | 2 | Completed | Sun Pharmaceutical Industries | Feb 27, 2017 | 53 |
| NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more | 4 | Completed | Sanofi | Mar 27, 2019 | 255 |
| NCT02405858Metastatic Castration-Resistant Prostate Cancer · Japan | 4 | Completed | Johnson & Johnson | Dec 31, 2017 | 51 |
| NCT02230046Healthy · United States | 1 | Completed | Johnson & Johnson | Nov 2014 | 102 |
| NCT02217566Prostatic Neoplasms · Brazil | 2 | Completed | Johnson & Johnson | Oct 26, 2018 | 46 |
| NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more | 1 | Active, not recruiting | Johnson & Johnson | Jun 27, 2016 | 57 |
| NCT02001571Prostatic Neoplasms · United States | 1 | Completed | Johnson & Johnson | Apr 2010 | 24 |
| NCT01873001Healthy Volunteers · Belgium | 1 | Completed | Johnson & Johnson | Jul 2013 | 16 |
| NCT01795703Prostatic Neoplasms · Japan | 2 | Completed | Johnson & Johnson | Oct 2014 | 47 |
| NCT01756638Prostatic Neoplasms · Japan | 2 | Completed | Johnson & Johnson | Oct 17, 2014 | 48 |
| NCT01715285Prostatic Neoplasms · Argentina, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Oct 31, 2016 | 1,209 |
| NCT01715259Renal Insufficiency · United States | 1 | Completed | Johnson & Johnson | Jan 2010 | 16 |
| NCT01798628Healthy Volunteers | 1 | Completed | Johnson & Johnson | Oct 2009 | 36 |
| NCT01695135Prostatic Neoplasms · China | 3 | Completed | Johnson & Johnson | Jun 20, 2014 | 214 |
| NCT01685983Prostatic Neoplasms · Korea, Republic of, Taiwan | 2 | Completed | Johnson & Johnson | Jan 24, 2013 | 82 |
| NCT01678573Healthy · China | 1 | Completed | Johnson & Johnson | Sep 2012 | 15 |
| NCT01664728Prostatic Neoplasms · United Kingdom | 1 | Completed | Johnson & Johnson | Feb 2009 | 54 |
| NCT01640093Healthy Participants · United States | 1 | Completed | Johnson & Johnson | Jul 2012 | 32 |
| NCT01591122Prostatic Neoplasms · China, Malaysia, Russian Federation and more | 3 | Completed | Johnson & Johnson | Dec 31, 2016 | 313 |
| NCT01655147Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2012 | 19 |
| NCT01517802Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Apr 22, 2021 | 32 |
| NCT01575587Pharmacology · United States | 1 | Completed | Johnson & Johnson | May 2012 | 51 |
| NCT01588782Healthy Volunteers · Belgium | 1 | Completed | Johnson & Johnson | Feb 2012 | 20 |
| NCT01511536Prostatic Neoplasms · United States, France, United Kingdom | 2 | Completed | Sanofi | Jul 2014 | 38 |
| NCT01495910Congenital adrenal hyperplasia due to 21 hydroxylase deficiency · United States | 1 | Completed | Johnson & Johnson | Feb 2013 | 6 |
| NCT01424930Prostatic Neoplasms · Canada | 2 | Completed | Johnson & Johnson | Apr 2013 | 25 |
| NCT01381874Breast Neoplasms · United States, Belgium, France and more | 2 | Completed | Johnson & Johnson | Jul 28, 2014 | 297 |
| NCT01362764Healthy Volunteers | 1 | Completed | Johnson & Johnson | Jun 2011 | 30 |
| NCT01314118Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Dec 24, 2013 | 131 |
| NCT01186484Prostatic Neoplasms · Japan | 1 | Completed | Johnson & Johnson | Oct 2, 2014 | 27 |
| NCT01017939Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Jun 2010 | 34 |
| NCT00924469Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Feb 2012 | 58 |
| NCT00910754Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Nov 2009 | 33 |
| NCT00887198Prostatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Mar 31, 2014 | 1,088 |
| NCT00638690Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Johnson & Johnson | Aug 2010 | 1,195 |
| NCT00600535Prostatic Neoplasms · United States, United Kingdom | 1 | Completed | Johnson & Johnson | Mar 2012 | 31 |
| NCT00544440Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Aug 2012 | 57 |
| NCT00485303Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Johnson & Johnson | Oct 2011 | 58 |
| NCT00474383Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Johnson & Johnson | Aug 2011 | 47 |
| NCT00473746Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Dec 2012 | 66 |
| NCT00473512Prostatic Neoplasms · United Kingdom | 2 | Completed | Johnson & Johnson | Nov 2008 | 54 |
How it is read
Names in the registry
- “Abiraterone acetate”, 24 entries
- “Abiraterone”, 10 entries
- “Abiraterone Acetate”, 5 entries
- “abiraterone acetate”, 2 entries
- “Abiraterone acetate (Treatment B)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 43 studies
- Neoplasm Metastasis, 2 studies
- Breast Neoplasms, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.